The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.
[fr] Récemment, les anticorps anti-gliadines déamidées ont supplanté les
anti-gliadines natives dans le diagnostic sérologique des patients coeliaques.
Cette étude a pour but d’évaluer la spécificité des frousses utilisant des peptides de gliadine déamidée et de la comparer à celle des tests basés sur la gliadine native. Les anticorps anti-gliadines natives, anti-gliadines déamidées et anti-transglutammase neo-epitope ont ete doses par cmq differentes techniques Elisa (IgA et IgG) quantitatives, ainsi que par un Eisa de screemng chez 46 patients non coeliaques. Les anticorps anti-gliadines natives IgA et 1gO sont trouvés chez 24 et 63 % des patients non coeliaques, respectivement. L’utilisation de la gliadine déamidée réduit le nombre de résultats faussement positifs en IgA et particulièrement en 1gO: 21 et 24 % respectivement des patients pour la frousse Anti-Gliadin (GAF-3X) Euroinunun, 7 et 26 % pour la frousse Bindazyme Euman Anti-Gliadin (MGP) fle Binding Site ainsi que O et 41 % pour la frousse Celiac G+ Immco. La trousse anti-transglutaminase néo-épitope, recherchant simultanément les anticorps anti-transglutaniinase, anti-gliadines déamidées et anti-néo-épitope, n’apporte pas une réelle aide au diagnostic différentiel de la maladie coeliaque car 30 % des patients présentent un résultat positif en 1gO contre 2 % en IgA. La frousse de screening d’Inova, recherchant simultanément les anticorps anti-transglutaniiuase et anti-gliadines déamidées, présente une positivité chez 24 % de la cohorte. En conclusion, le dosage des anticorps anti-gliadines déamidées paraît être la méthode de choix pour sa plus grande spécificité face aux anticorps anti-gliadines natives dans le diagnostic différentiel de la maladie coeliaque. [en] Recently, anti-deamidated gliadin antihodies were proposed for the serological diagnosis of celiac disease. We evaluate the specificity of different anti-deamidated gliadin antibodies ELISA in comparison with conventional anti-native gliadin kits. Serum sainples froin 46 non celiac patients trere analyzed by five different quantitative ELISA for anti-native gliadin, antideamidated gliadin and anti-fransglutaininase neo-epitope antibodies together with a screening ELISA. Twenty-four percent of the patients deinonstrated anti-native gliadin lgA and 63% 1gO antibodies. Using anti-dearnidated gliadin antibodies, tire number of false positive IgA and, particularly, 1gG results,markedly decreased in the non celiac patients: 21 and 24% respectively with anti-Gliadin (GAF-3X) Euroimmun kit, 7 and 26% with Bindazyme 1-lurnan Anti-Gliadin (MGP) The Binding Site kit and 0 and 41% with Celiac G+ Immco kit. The new assay which makes use of the physiological complex of tissue transglutaminase cross-linked with deamidated gliadin peptides, called neo-epitope, did not improve the differential diagnosis of celiac disease with 30% of false positive results in IgG (2% in IgA). IJsing the Inova screening kit, a positive resuit for IgA and/or IgG anti-deamidated gliadin and!or anti- tissue transglutaminase antibodies was obtained in 24% of the non celiac patients. In conclusion, our study assessed the superiority, in ternis of specificity, of anti-deamidated gliadin antibodies, over the conventional anti-gliadin antibodies for die differential diagnosis of celiac disease.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43.
Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J Exp Med 1989;169:345-50.
van Heel DA, West J. Recent advances in coeliac disease. Gut 2006;55:1037-46.
Dewar D, Pereira SP, Ciclitira PJ. The pathogenesis of coeliac disease. Int J Biochem Cell Biol 2004;36:17-24.
Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990;65:909-11.
Chorzelski TP, Sulej J, Tchorzewska H, Jablonska S, Beutner EH, Kumar V. IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann NY Acad Sci 1983;420:325-34.
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
Carroccio A, Vitale G, Di Prima L, Chifari N, Napoli S, La Russa C, et al. Comparison of anti-transglutaminase ELISA and an antiendomysial antibody assay in the diagnosis of celiac disease : a prospective study. Clin Chem 2002;48:1546-50.
Unsworth DJ, Manuel PD, Walker-Smith JA, Campbell CA, Johnson GD, Holborow EJ. New immunofluorescent blood test for gluten sensitivity. Arch Dis Child 1981;56:864-8.
Aleanzi M, Demonte AM, Esper C, Garcialazo S, Waggener M. Celiac disease : antibody recognition against native and selectively deamidated gliadin peptides. Clin Chem 2001;47:2023-8.
Schwertz E, Kahlenberg F, Sack U, Richter T, Stern M, Conrad K, et al. Serologic assay based on gliadin-related nonapeptides as a highly sensitive and specific diagnostic aid in celiac disease. Clin Chem 2004;50:2370-5.
Skovbjerg H, Koch C, Anthonsen D, Sjöström H. Deamidation and cross-linking of gliadin peptides by transglutaminases and the relation to celiac disease. Biochim Biophys Acta 2004;1690:220-30.
Fleckenstein B, Qiao SW, Larsen MR, Jung G, Roepstorff P, Sollid LM. Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides. J Biol Chem 2004;279:17607-16.
Volta U, Granito A, Fiorini E, Parisi C, Piscaglia M, Pappas G, et al. Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. Dig Dis Sci 2008;53:1582-8.
Prince HE. Evaluation of the INOVA diagnostics enzyme-linked immunosorbent assay kits for measuring serum immunoglobulin G (IgG) and IgA to deamidated gliadin peptides. Clin Vaccine Immunol 2006;13:150-1.
Reeves GE, Squance ML, Duggan AE, Murugasu RR, Wilson RJ, Wong RC, et al. Diagnostic accuracy of coeliac serological tests : a prospective study. Eur J Gastroenterol Hepatol 2006;18:493-501.
Rashtak S, Ettore MW, Homburger HA, Murray JA. Combination testing for antibodies in the diagnosis of coeliac disease : comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther 2008;28:805-13.
Villalta D, Alessio MG, Tampoia M, Tonutti E, Brusca I, Bagnasco M, et al. Testing for IgG class antibodies in celiac disease patients with selective IgA deficiency. A comparison of the diagnostic accuracy of 9 IgG anti-tissue transglutaminase, 1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide antibody assays. Clin Chim Acta 2007;382:95-9.
